

Special Issue

Obesity-Related Gastrointestinal Disorders: Uncovering Mechanisms Behind Cardiometabolic Improvement with Weight Loss

Message from the Guest Editor

Obesity and its associated cardiometabolic comorbidities remain significant drivers of chronic gastrointestinal (GI) diseases. For this Special Issue, we welcome submissions that elucidate the underlying mechanisms by which weight loss via different modalities (e.g., AOMs and endoscopic procedures) confers cardiometabolic benefits. We encourage articles that explore innovative techniques for weight management and improvements in cardiometabolic health, highlighting the role of gut hormones and investigating how these procedures modulate GI function in the context of broader metabolic health. By focusing on a range of methodological approaches—ranging from basic research to multidisciplinary collaborations—this Special Issue will advance our understanding of the complex relationships among obesity, chronic GI disease, and cardiometabolic risk. By providing a more comprehensive view of these interconnections, the Special Issue will facilitate the development of improved therapeutic strategies for patients with obesity-related GI disorders.

Guest Editor

Dr. Wissam Ghushn

1. Department of Internal Medicine, Boston Medical Center, Boston, MA, USA

2. Division of Gastroenterology, Mayo Clinic Hospital, Rochester, MN, USA

Deadline for manuscript submissions

31 October 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



mdpi.com/si/237313

Biomedicines

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

biomedicines@mdpi.com

mdpi.com/journal/

[biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).